
-
The Growing Appetite For Obesity Drugs4/3/2023
New obesity drugs with unprecedented efficacy are coming into the market. Can they turn the tide in the global obesity epidemic?
-
U.S. Patent Expired? Why Not Grow Revenue Globally, Says Amarin4/3/2023
Amarin is deploying a global strategy to expand patient access to Vascepa, hoping to make up for lost revenues in the U.S.
-
Making The Right Deal For Biohaven3/1/2023
Biohaven CEO Vlad Coric describes the events leading up to Pfizer’s $11.6 billion acquisition, his drug launch during the start of COVID-19, and why company titles and seniority don’t really matter.
-
Translating Nobel Prize Winning Science Into Medicine3/1/2023
2022 Nobel Prize winner Carolyn Bertozzi discusses her approach to translating scientific discoveries into biopharmaceutical products, and her ongoing partnership with Shasqi CEO José Mejía Oneto.
-
Commercialization Or Bust?3/1/2023
If you’re a biotech in the earlier stages of clinical development, is it now incumbent upon leadership to build out the capabilities necessary for regulatory submission and commercialization, in case the right deal doesn’t materialize?
-
Choosing Your Battles2/1/2023
Should business leaders speak out on the social and political issues that intermingle with the buying and selling of goods and services? Opinions vary … widely.
-
With Fundraising, A Track Record Matters: GeoVax's David Dodd2/1/2023
Industry veteran David Dodd, chairman and CEO at GeoVax, answers questions about the fundraising environment for small biotechs, and the dangers of toxic warrants.
-
Why Takeda Is Focusing So Much On Plasma-Derived Therapies2/1/2023
Tasked with driving future growth of Takeda’s plasma-derived therapies, Giles Platford, business unit president, shares his approach to partnering, promoting market access, and improving patient experiences.
-
Verve Therapeutics: How To Build A Gene Editing Biotech1/3/2023
Verve Therapeutics’ co-founder and CEO Sekar Kathiresan offers insight into how he launched a gene editing drug company and dosed the first patient in less than four years.